Who Owns Halozyme Therapeutics Stock?
NASDAQ: HALOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 113.13%
- Institutions (% of float)
- 114.37%
- Held by insiders
- 1.08%
- Institutional holders
- 913
- Institutions 98.9%
- Insiders 1.1%
- Public and other 0.0%
Who owns Halozyme Therapeutics stock?
Institutional investors own about 113.1% of Halozyme Therapeutics's shares, spread across 913 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 1.08% of HALO.
The largest institutional holders are Blackrock Inc. (11.69%), Vanguard Capital Management LLC (4.71%) and Vanguard Portfolio Management LLC (4.67%). Together, the top 10 institutions control 40.2% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their HALO positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of HALO
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 13.27M | 11.69% | +0.1% |
| Vanguard Capital Management LLC | 5.35M | 4.71% | +1.5% |
| Vanguard Portfolio Management LLC | 5.30M | 4.67% | +0.9% |
| State Street Corporation | 5.18M | 4.56% | +4.9% |
| Invesco Ltd. | 3.18M | 2.80% | -20.8% |
| Morgan Stanley | 2.83M | 2.50% | +10.6% |
| Boston Partners | 2.77M | 2.44% | +3.4% |
| Bank of America Corporation | 2.74M | 2.41% | -5.9% |
| Geode Capital Management, LLC | 2.52M | 2.22% | +0.6% |
| William Blair Investment Management, LLC | 2.51M | 2.21% | -0.6% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of HALO
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 4.15M | 3.66% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.76M | 3.32% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.72M | 2.40% |
| John Hancock Funds III-Disciplined Value Mid Cap Fund | 1.68M | 1.48% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.57M | 1.38% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.49M | 1.31% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.36M | 1.20% |
| AIM Counselor Series TRT -Invesco Discovery Fd. | 1.25M | 1.10% |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 1.19M | 1.05% |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Growth Fund | 968.75K | 0.85% |
Frequently asked questions
Who is the largest shareholder of Halozyme Therapeutics?
Blackrock Inc. is the largest institutional shareholder of HALO, owning 11.69% of shares outstanding (13.27M shares) as of its latest 13F filing.
What percentage of Halozyme Therapeutics is owned by institutions?
Institutions own about 113.1% of HALO shares and 114.4% of the public float.
How much of Halozyme Therapeutics do insiders own?
Insiders, such as officers and directors, own about 1.08% of HALO shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.